Seahorse is developing the Cell Doctor™, an unprecedented system capable of measuring cell viability, cell metabolism, and other valuable cell parameters in a non-invasive manner. This product platform targets the large and rapidly growing high-throughput Cell-Based Assay market in drug discovery and development. The Company is working closely with a customer design team including scientists from eight of the top ten pharmaceutical companies to launch its system in 2005. In addition, CEO Jay Teich is driving revenue growth for Seahorse’s proprietary microplate product line. Flagship Partner David Stone is Director.

www.seahorsebioscience.com